ClinicalTrials.gg
CompletedNCT03261960Updated Sep 8, 2021Results posted

A Safety and Efficacy Comparison of BLI4700 Bowel Preparation Versus an FDA-approved Comparator in Adult Subjects Prior to Colonoscopy

A Phase 3 interventional study of BLI4700 and Magnesium bowel preparation in Colonoscopy, sponsored by Braintree Laboratories. Completed at 20 sites in United States. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2021-09-08.

Sponsored by Braintree Laboratories (part of Sebela Pharmaceuticals) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
389
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Study summary

The objective of this study is to compare the safety and efficacy of BLI4700 bowel preparation to an FDA-approved bowel preparation as 2-day, split-dose bowel preparations prior to colonoscopy in adult patients.

02

Conditions studied

  • Colonoscopy
03

In context

Lead sponsor

Braintree Laboratories is the lead sponsor of 49 studies on the registry; none are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 7 (70%) have results posted.

First submitted before Braintree Laboratories became part of Sebela Pharmaceuticals.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female outpatients who are undergoing colonoscopy for a routinely accepted indication.
  • 18 to 85 years of age (inclusive)
  • If female, and of , is using an acceptable form of (hormonal birth control, IUD, double-barrier method, depot contraceptive, abstinent, or vasectomized spouse).
  • Negative serum pregnancy test at screening, if applicable
  • In the Investigator's judgment, subject is mentally competent to provide to participate in the study

Exclusion criteria

Exclusion Criteria:

  • Subjects with known or suspected ileus, gastrointestinal obstruction, gastroparesis, gastric retention, bowel perforation, toxic colitis or megacolon.
  • Subjects with ongoing severe, acute inflammatory bowel disease
  • Subjects who had previous significant gastrointestinal surgeries.
  • Subjects with uncontrolled pre-existing electrolyte abnormalities, or those with electrolyte abnormalities based on Visit 1 laboratory results.
  • Subjects taking diuretics, anti-hypertensive medications, including angiotensin converting enzyme (ACE) inhibitors and Angiotensin II receptor blockers (ARBs), or chronic NSAIDs, that have not been stable for 30 days. NSAID use for occasional pain is not exclusionary.
  • Subjects with uncontrolled hypertension (systolic blood pressure > 170 mmHg and diastolic blood pressure > 100 mmHg).
  • Subjects taking antibiotics within 7 days of colonoscopy.
  • Subjects with severe renal insufficiency ( \< 30 mL/min/1.73m2).
  • Subjects with known severe hepatic insufficiency ( C)
  • Subjects with cardiac insufficiency ( Functional Classifications 3 or 4).
  • Subjects with an abnormal and clinically significant physical examination or finding at Visit 1.
  • Subjects undergoing insulin therapy for any indication.
  • Subjects with impaired consciousness that predisposes them to pulmonary aspiration.
  • Subjects undergoing colonoscopy for foreign body removal and/or decompression.
  • Subjects who are pregnant or lactating, or intending to become pregnant during the study.
  • Subjects of who refuse a pregnancy test.
  • Subjects allergic to any preparation component.
  • Subjects using drugs of abuse, including abused prescription medications.
  • Subjects who are withdrawing from alcohol or benzodiazepines.
  • Subjects who, in the opinion of the Investigator, should not be included in the study for any reason, including inability to follow study procedures.
  • Subjects who have participated in an surgical, drug, or device study within the past 30 days.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
389 participants (actual)

Study arms

  • Experimental
    Experimental Arm

    BLI4700 Bowel Preparation

    Drug: BLI4700

  • Active comparator
    Control Arm

    FDA Approved Bowel Preparation

    Drug: Magnesium bowel preparation

Interventions

  • Oral bowel preparation

  • DrugMagnesium bowel preparation

    Oral bowel preparation

06

What researchers measure

Primary outcomes

  1. Number and Percentage of Subjects With Successful Bowel Cleansing

    % of subjects with successful bowel preparation rated by colonoscopist on a 4 point scale (1=poor to 4=excellent)

    Time frame: Day of colonoscopy

Other outcomes

  1. Abdominal Pain (Solicited Reports)

    Percentage of patients who reported abdominal pain (with associated severity) when directly queried by study personnel, out of all patients that reported that event.

    Time frame: 2 days

  2. Abdominal Distension (Solicited Reports)

    Percentage of patients who reported abdominal distension (with associated severity) when directly queried by study personnel, out of all patients that reported that event.

    Time frame: 2 days

  3. Nausea (Solicited Reports)

    Percentage of patients who reported nausea (with associated severity) when directly queried by study personnel, out of all patients that reported that event.

    Time frame: 2 days

  4. Vomiting (Solicited Reports)

    Percentage of patients who reported vomiting (with associated severity) when directly queried by study personnel, out of all patients that reported that event.

    Time frame: 2 days

07

Results

Posted Sep 8, 2021

Participant flow

Participant flow — Overall Study
MilestoneExperimental ArmControl Arm
Started190199
Completed176185
Not completed1414

Outcome measures

PrimaryNumber and Percentage of Subjects With Successful Bowel Cleansing

% of subjects with successful bowel preparation rated by colonoscopist on a 4 point scale (1=poor to 4=excellent)

Time frame:
Day of colonoscopy
Reported as:
Count of participants · Participants
Number and Percentage of Subjects With Successful Bowel Cleansing
ParticipantsExperimental ArmControl Arm
Number and Percentage of Subjects With Successful Bowel Cleansing175174
Statistical analysis
  • Experimental Arm vs Control Arm · Cochran-Mantel-Haenszel · p = <0.001
Other pre-specifiedAbdominal Pain (Solicited Reports)

Percentage of patients who reported abdominal pain (with associated severity) when directly queried by study personnel, out of all patients that reported that event.

Time frame:
2 days
Reported as:
Number · percentage of patients
Abdominal Pain (Solicited Reports)
percentage of patientsExperimental ArmControl Arm
Mild82100
Moderate160
Severe20
Other pre-specifiedAbdominal Distension (Solicited Reports)

Percentage of patients who reported abdominal distension (with associated severity) when directly queried by study personnel, out of all patients that reported that event.

Time frame:
2 days
Reported as:
Number · percentage of patients
Abdominal Distension (Solicited Reports)
percentage of patientsExperimental ArmControl Arm
Mild7369
Moderate2731
Severe00
Other pre-specifiedNausea (Solicited Reports)

Percentage of patients who reported nausea (with associated severity) when directly queried by study personnel, out of all patients that reported that event.

Time frame:
2 days
Reported as:
Number · percentage of patients
Nausea (Solicited Reports)
percentage of patientsExperimental ArmControl Arm
Mild7494
Moderate206
Severe60
Other pre-specifiedVomiting (Solicited Reports)

Percentage of patients who reported vomiting (with associated severity) when directly queried by study personnel, out of all patients that reported that event.

Time frame:
2 days
Reported as:
Number · percentage of patients
Vomiting (Solicited Reports)
percentage of patientsExperimental ArmControl Arm
Mild5333
Moderate4767
Severe00

Adverse events

Collected over 30 days. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Experimental Arm0/190 (0%)0/190 (0%)5/190 (2.6%)
Control Arm0/199 (0%)1/199 (0.5%)2/199 (1%)
Most frequent serious events
Most frequent serious events
EventExperimental ArmControl Arm
CholelithiasisHepatobiliary disorders0/1901/199
Most frequent other events
Most frequent other events
EventExperimental ArmControl Arm
Liver function test increasedInvestigations5/1902/199

Baseline characteristics

Safety population - all patients that took preparation.

Age, Categorical
Age, Categorical(Participants)Experimental ArmControl ArmTotal
<=18 years000
Between 18 and 65 years128152280
>=65 years6247109
Age, Continuous
Age, Continuous(years)Experimental ArmControl ArmTotal
Mean58.2 ± 11.257.3 ± 10.857.8 ± 11.0
Sex: Female, Male
Sex: Female, Male(Participants)Experimental ArmControl ArmTotal
Female112113225
Male7886164
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Experimental ArmControl ArmTotal
Hispanic or Latino191635
Not Hispanic or Latino171183354
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Experimental ArmControl ArmTotal
American Indian or Alaska Native213
Asian224
Native Hawaiian or Other Pacific Islander011
Black or African American81119
White177183360
More than one race000
Unknown or Not Reported112
Region of Enrollment
Region of Enrollment(participants)Experimental ArmControl ArmTotal
United States190199389
Renal Insufficiency (GFR < 60)
Renal Insufficiency (GFR < 60)(Participants)Experimental ArmControl ArmTotal
Count of participants161430
Diabetic
Diabetic(Participants)Experimental ArmControl ArmTotal
Count of participants201434
08

Study locations

20 sites
  • Braintree Research Site 119
    Dothan, Alabama 36305, United States
  • Braintree Research Site 117
    Tucson, Arizona 85710, United States
  • Braintree Research Site 108
    Little Rock, Arkansas 72117, United States
  • Braintree Research Site 110
    Little Rock, Arkansas 72211, United States
  • Braintree Research Site 139
    Palmetto Bay, Florida 33157, United States
  • Braintree Research Site 124
    Oak Lawn, Illinois 60453, United States
  • Braintree Research Site 134
    Indianapolis, Indiana 46202, United States
  • Braintree Research Site 112
    Chevy Chase, Maryland 20815, United States
  • Braintree Research Site 141
    Towson, Maryland 20214, United States
  • Braintree Research Site 125
    Chesterfield, Missouri 48047, United States
  • Braintree Research Site 102
    Saint Louis, Missouri 63128, United States
  • Braintree Research Site 145
    Egg Harbor Township, New Jersey 08234, United States
  • Braintree Research Site 114
    Poughkeepsie, New York 12601, United States
  • Braintree Research Site 105
    Asheville, North Carolina 28801, United States
  • Braintree Research Site 115
    Charlotte, North Carolina 28207, United States
  • Braintree Research Site 137
    Raleigh, North Carolina 27607, United States
  • Braintree Research Site 101
    Raleigh, North Carolina 27612, United States
  • Braintree Research Site 107
    Greenville, South Carolina 29615, United States
  • Braintree Research Site 131
    Charlottesville, Virginia 22911, United States
  • Braintree Research Site 121
    Bellevue, Washington 98004, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2017 to primary completion in Mar 2018, 7 months.

Results were first posted in Sep 2021, 3 years 5 months after primary completion. A results delay was requested in Sep 2019.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 23, 2017
First posted
Aug 25, 2017
StartActual
Aug 8, 2017
Primary completionActual
Mar 26, 2018
CompletionActual
Mar 26, 2018
Results delay requested
Sep 27, 2019
Results first posted
Sep 8, 2021
Last update
Sep 8, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 8, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03261960
Responsible party
Sponsor
First posted
Aug 25, 2017
Start date
Aug 8, 2017
Primary completion
Mar 26, 2018
Completion
Mar 26, 2018
Results posted
Sep 8, 2021
Last update
Sep 8, 2021

Study contacts

John McGowan, MPH
study director · Braintree Laboratories, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BLI4700

Start the discussion